Get the Stockscreener App
3.82
5.23%
0.19
After Hours:
3.85
0.03
+0.79%
Aclaris Therapeutics Inc stock is traded at $3.82, with a volume of 826.84K.
It is up +5.23% in the last 24 hours and up +126.04% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
See More
Previous Close:
$3.63
Open:
$3.64
24h Volume:
826.84K
Relative Volume:
0.40
Market Cap:
$264.29M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-2.4645
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
-3.54%
1M Performance:
+126.04%
6M Performance:
+244.14%
1Y Performance:
+339.13%
1-Day Range:
$3.64
$3.94
1-Week Range:
$3.625
$4.55
52-Week Range:
$0.80
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.82 | 264.29M | 31.25M | -88.48M | -79.63M | -1.55 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Wayne’s Aclaris Therapeutics Signs Exclusive Licensing Deal with Chinese Biotech - MSN
Equities Analysts Set Expectations for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MSN
Aclaris Therapeutics secures global rights to Biosion’s antibodies - MSN
Rock Springs Capital Management LP Increases Stake in Aclaris Th - GuruFocus.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Aclaris upgraded to overweight by Cantor on in-licensing deal - MSN
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Aclaris Therapeutics enters into exclusive license agreement for two drugs - Pennsylvania Business Report
What is Leerink Partnrs' Estimate for ACRS FY2024 Earnings? - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Leerink Partners - Defense World
Insider Buying: Anand Mehra Acquires Shares in Aclaris Therapeutics Inc (ACRS) - GuruFocus.com
Aclaris Therapeutics director acquires $1.5 million in stock By Investing.com - Investing.com Canada
Aclaris Therapeutics director acquires $1.5 million in stock - Investing.com India
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Leerink Partnrs to Strong-Buy Rating - MarketBeat
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - MSN
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - MSN
S&P 500 Value (IVX) QuotePress Release - The Globe and Mail
Aclaris signs license deal for biologics assets - MSN
Aclaris stock soars for second day on licensing deal, analyst upgrades - MSN
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG Research - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Jefferies Financial Group to “Buy” Rating - Defense World
Aclaris stock sees over 120% upside potential with bolstered immunology assets - Investing.com India
Aclaris Therapeutics Enters Exclusive Agreements and Announces Private PlacementWAYNE, Pa., Nov. 16, 2024 /PRNewswire/ — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has recently entered into significant agreements and a private placement. On Nov - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Raised to “Overweight” at Piper Sandler - Defense World
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
S&P 500 Utilities [Sector] (SRUT) QuotePress Release - The Globe and Mail
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG - Yahoo Finance
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Yahoo Finance
Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News - MarketWatch
Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha
Aclaris gains global rights to Biosion's inflammatory treatment candidates By Investing.com - Investing.com UK
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps - MSN
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBioNTech (NASDAQ:BNTX) - Benzinga
Aclaris back on track with new money and promising deal - The Pharma Letter
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Outperform at Leerink Partners - MarketBeat
BTIG Upgrades Aclaris Therapeutics (ACRS) - MSN
Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink - TipRanks
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at Jefferies Financial Group - MarketBeat
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here - Head Topics
Aclaris to license Biosion’s two biologics assets for up to $940m - World Pharmaceutical Frontiers
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
| Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):